

29. (Previously Amended) A tissue adhesive comprising fibrinogen and an admixed elastase inhibitor.

30. (Original) A tissue adhesive as set forth in claim 29, wherein said elastase inhibitor is selected from the group consisting of eglin, elastase- α 1-proteinase inhibitor, α 1-antiprotease, leukocyte protease inhibitor, elafin and mixtures thereof.

31. (Withdrawn)

32. (Withdrawn)

33. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is comprised of human proteins.

34. (Withdrawn)

35. (Withdrawn)

36. (Previously Amended) A tissue adhesive as set forth in claim 29, wherein the ratio in weight of said elastase inhibitor to said fibrinogen is from 1:100 to 1:150,000.

37. (Previously Amended) A tissue adhesive as set forth in claim 29, wherein the ratio in weight of said elastase inhibitor to said fibrinogen is from 1:500 to 1:110,000.

38. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive contains at least 10^{-6} U of elastase inhibitor per gram of fibrinogen.

39. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive contains from between 10^{-3} and 10 U of elastase inhibitor per gram of fibrinogen.

40. (Original) A tissue adhesive as set forth in claim 29, further comprising plasminogen in an amount of at least 0.0001 mg/mg of fibrinogen.

41. (Original) A tissue adhesive as set forth in claim 40, wherein said plasminogen is contained in an amount of at least 0.001 mg/mg of fibrinogen.

42. (Original) A tissue adhesive as set forth in claim 40, wherein said plasminogen is contained in an amount of more than 0.01 mg/mg of fibrinogen.

43. (Withdrawn)

44. (Withdrawn)

45. (Withdrawn)

46. (Withdrawn)

47. (Withdrawn)

48. (Withdrawn)

49. (Withdrawn)

50. (Withdrawn)

51. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is free from kininogenic proteins.

52. (Withdrawn)

53. (Withdrawn)

54. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is resistant to lysis in an environment with high activity for a period of time which is at least 10 hours.

55. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is resistant to lysis in an environment with high fibrinolytic activity for a period of time which is at least 15 hours.

56. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is lyophilized.

57. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue is present in solution.

58. (Original) A tissue adhesive as set forth in claim 57, wherein said solution is deep-frozen.

59. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is present in virus-inactivated form.

60. (Original) A tissue adhesive as set forth in claim 29, wherein said elastase inhibitor is of recombinant origin.

61. (Withdrawn)

62. (Withdrawn)

63. (Withdrawn)

64. (Withdrawn)

65. (Withdrawn)

66. (Withdrawn)

67. (Withdrawn)

68. (Withdrawn)

69. (Withdrawn)

70. (Original) A method for treating wounds or hemorrhages with high fibrinolytic activity in patients, comprising administering an effective dose of a tissue adhesive preparation containing fibrinogen and an elastase inhibitor.

71. (Original) A method as set forth in claim 70, wherein said wound of hemorrhage is urological.

72. (Original) A method for treating wounds or hemorrhages in patients, comprising administering an effective dose of a tissue adhesive containing fibrinogen and an elastase inhibitor by means of an application device.

73. (Original) A method as set forth in claim 72, wherein said wound or hemorrhage is urological.